| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 5, 2014Fourth-quarter net sales up 7%; Medical Devices sales up 8%
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 5, 2014-- Covidien plc (NYSE: COV) today announced financial results for the fourth quarter of fiscal 2014. Fourth-quarter net sales of $2.73 billion...
-
Nov 5, 2014EverFlex™ Self-Expanding Stent System Safe and Effective for the Treatment of Iliac Stenosis
LAS VEGAS--(BUSINESS WIRE)--Nov. 5, 2014-- Covidien plc (NYSE: COV) today announced nine-month results of the DURABILITY Iliac study and addition of the iliac indication for its EverFlex™ stent...
-
Nov 4, 2014Employee Engagement, Philanthropy Among Top Reasons for Selection
BRAMPTON, ONTARIO - November 4, 2014 - Medtronic of Canada Ltd., a trusted Canadian leader in innovative medical technologies and health system solutions, is pleased to have been recognized as one...
-
Nov 4, 2014Results suggest long-term benefits for peripheral artery disease patients treated with directional atherectomy followed by a drug-coated balloon
LAS VEGAS--(BUSINESS WIRE)--Nov. 4, 2014-- Covidien plc (NYSE: COV) today announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical...
-
Nov 2, 2014Expands Spectranetics' portfolio of solutions to treat complex vascular conditions in projected $700 million drug coated balloon segment
COLORADO SPRINGS, Colo., and DUBLIN, Ireland, Nov. 2, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) and Covidien plc (NYSE:COV) today announced a definitive agreement under...